Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more

In this roundtable discussion, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Tycel Phillips, MD, City of Hope, Duarte, CA, provide updates on the management of mantle cell lymphoma (MCL). The experts discuss frontline therapy for MCL, the evolving role of autologous stem cell transplantation (autoSCT), treatment sequencing, and the value of measurable residual disease (MRD) in this hematological malignancy. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.